A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung

Hum Gene Ther. 1995 May;6(5):643-66. doi: 10.1089/hum.1995.6.5-643.

Authors

R G Crystal¹, A Jaffe, S Brody, A Mastrangeli, N G McElvaney, M Rosenfeld, C S Chu, C Danel, J Hay, T Eissa

Affiliation

¹ Rockefeller University Hospital, New York, New York 10021, USA.

PMID: 7578401
DOI: 10.1089/hum.1995.6.5-643

No abstract available

MeSH terms

Adenoviridae / genetics*
Adult
Bronchi / metabolism
Clinical Protocols
Clinical Trials, Phase I as Topic*
Cystic Fibrosis / genetics
Cystic Fibrosis / therapy*
Cystic Fibrosis Transmembrane Conductance Regulator / biosynthesis
Cystic Fibrosis Transmembrane Conductance Regulator / genetics*
DNA, Complementary / genetics
Epithelium / metabolism
Female
Gene Transfer Techniques*
Genetic Therapy* / adverse effects
Genetic Vectors
Humans
Male
Nasal Mucosa / metabolism
Patient Selection
Recombinant Proteins / genetics
Virus Replication

Substances

CFTR protein, human
DNA, Complementary
Recombinant Proteins
Cystic Fibrosis Transmembrane Conductance Regulator